Healthcare >> CEO Interviews >> January 22, 2001
DR. LOUIS LAMONTAGNE is President and CEO of Neurochem Inc. He oversees
Neurochem's management team and is responsible for setting the company's
vision and strategies for drug development, manufacturing, and
regulatory affairs. Dr. Lamontagne holds a PhD in Immunochemistry and
Immunology from McMaster University, Hamilton and a BSc Honours
Chemistry from Queen's University, Kingston. Dr. Lamontagne's academic
studies focused on the induction of acute phase reactants (serum amyloid
A and P, CRP, etc.). After his PhD, Dr. Lamontagne joined Harvard
University's School of Public Health to research tropical parasitic
diseases. In the biotechnology sector, Dr. Lamontagne held several
senior positions (including Director of R&D and Product Development) at
Chembiomed Ltd., a biotechnology company involved in the development of
therapeutic products for the treatment of Hemolytic disease of the
newborn and for the prevention of organ rejections in ABO incompatible
transplants. Dr. Lamontagne has also held several other key management
positions, including Director, Institute for Biological Sciences at the
National Research Council and, President and CEO, Ottawa Life Sciences
Technology Centre. Profile
a history, your involvement and business description of Neurochem?
Dr. Lamontagne: Neurochem is a biopharmaceutical
